There are currently 58 clinical trials in Macon, Georgia looking for participants to engage in research studies. Trials are conducted at various facilities, including Medical Center of Central Georgia, Atrium Health Navicent, GSK Investigational Site and Central Georgia Gynecologic Oncology. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases
NCT06076642
Recruiting
The main aim of this study is to learn if TAK-881 is safe and well tolerated during long-term use in adults and children with PIDD who are eligible and completed study TAK-881-3001 (NCT05755035). The participants will receive the first dose of TAK-881 immunoglobulin (IgG) infusion at the same dosage as the last dose administered in study TAK-881-3001 (NCT05755035). After the first TAK-881 infusion in study TAK-881-3002, the dosing interval (can be adjusted by participant/caregiver) and/or the d... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
12/19/2024
Locations: Central Georgia Infectious Disease Consultants, Macon, Georgia
Conditions: Primary Immunodeficiency Diseases (PID)
Register for Updates
F15 Recharge Free Axonics SNM System Clinical Study
NCT06186765
Recruiting
Multicenter, prospective, non randomized, single arm evaluation of patients with overactive bladder (OAB) and/or fecal incontinence (FI) employing the Axonics recharge free SNM System.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/13/2024
Locations: Atrium Health, Macon, Georgia
Conditions: Urinary Urge Incontinence (UUI), Fecal Incontinence (FI), Urinary Frequency (UF)
Register for Updates
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
NCT05158387
Recruiting
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12 months. Participants should be receiving optimised treatment with maintenance inhaled therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) in stable doses throughout at least 3 months prior... Read More
Gender:
ALL
Ages:
Between 40 years and 130 years
Trial Updated:
11/27/2024
Locations: Research Site, Macon, Georgia
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Register for Updates
Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism
NCT06531941
Recruiting
The purpose of this study is to evaluate the long-term safety and tolerability of MBX 2109 in patients with hypoparathyroidism who completed the 12-week treatment period in the Phase 2 study, MBX-2H1002.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
11/11/2024
Locations: MBX Biosciences Investigational Site, Macon, Georgia
Conditions: Hypoparathyroidism
Register for Updates
Primary Subtalar Arthrodesis for Calcaneal Fractures
NCT06249126
Recruiting
Management of severe injuries to the heel (displaced intra-articular calcaneus fractures) continues to be a major challenge for orthopedic surgeons. Previous studies have demonstrated poor outcomes, and results show that patients experience long-term pain and decreased quality of life postoperatively. Poor outcomes are driven by pain, in particular, which is linked to post-traumatic subtalar arthritis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: Atrium Health Navicent, Macon, Georgia
Conditions: Calcaneus Fracture
Register for Updates
A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases
NCT05755035
Recruiting
The main aim of this study is to evaluate the PK, safety, tolerability and immunogenicity of subcutaneous (SC) administration of TAK-881 in adult and pediatric participants with PIDD and compare them to HYQVIA in participants 16 years old and older. The participants will be treated with TAK-881/HYQVIA or HYQVIA/TAK-881 with the same dose and dosing interval of immunoglobulin for up to 51 weeks (for participants greater than or equal to \[\>=\]16 years) and only with TAK-881 for up to 27 weeks (... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
10/04/2024
Locations: Central Georgia Infectious Disease Consultants, Macon, Georgia
Conditions: Primary Immunodeficiency Diseases (PID)
Register for Updates
Prophylactic Antibiotic Coated Nail to Prevent Infection: A Clinical Trial
NCT05421741
Recruiting
This prospective randomized clinical trial will compare outcomes between patients treated primarily with a prophylactic antibiotic coated nail and those treated with traditional standard of care intramedullary (IM) nailing.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2024
Locations: Atrium Health Navicent, Macon, Georgia
Conditions: Osteomyelitis Tibia, Tibial Fractures, Open tíbia Fracture
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Central Georgia Gynecologic Oncology, Macon, Georgia +1 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
A Phase 2 Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain (CYPRESS)
NCT05895552
Recruiting
This is a 2-part, randomized, placebo-controlled, double-blind, Phase 2 study to evaluate the safety, tolerability, efficacy, and pharmacokinetics (PK) of RTA 901 in qualified participants with Diabetic Peripheral Neuropathic Pain (DPNP). Each study part will be randomized into 3 treatment arms; 2 different doses of RTA 901 and RTA 901-maching placebo. The doses of RTA 901 in Part 2 will be selected based on the Exposure-Response (E-R) analyses of data from Part 1. A total of 384 participants wi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/28/2024
Locations: East Coast Institute for Research, LLC, Macon, Georgia
Conditions: Diabetic Peripheral Neuropathic Pain
Register for Updates
A Study to Investigate Leramistat in Patients With IPF
NCT05951296
Recruiting
To compare the effect of daily oral dosing of leramistat over 12 weeks with placebo in participants aged 40 years or older with idiopathic pulmonary fibrosis (IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
02/16/2024
Locations: Southern Medical Research, LLC, Macon, Georgia
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates